Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Sourcebio International in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Sourcebio International. This rating has held steady since April 2023, when it changed from a Buy consensus rating.
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. The company's services cover histopathology cancer screening and clinical diagnostic services; DNA sequencing services and precision medicine to pharmaceutical and biotechnology companies, academia, contract research organizations, and other research markets; shelf-life testing services and equipment; and COVID-19 antigen PCR testing services. It also manufactures library clones, direct to consumer home test kits, and blood and tissue serological products; and provides employee testing solutions and venue testing. In addition, the company offers controlled environment storage services and diagnostic and genomic services and products. Sourcebio International Plc was founded in 1999 and is headquartered in Nottingham, the United Kingdom.
Read More
